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Amyloid fibrils deposited in secondary amyloidosis contain a  unique protein 
(AA)  as  the  major  constituent  (1-3).  An  antigenically  related  serum  protein 
(SAA)  (4,  5),  present  in  normal  sera  in  low concentration  (6),  is  elevated in 
amyloidosis and in diseases which predispose to amyloidosis, such as rheuma- 
toid arthritis,  leprosy, and tuberculosis (4-8). 
The finding that SAA has a monomeric form about 50% larger than AA (9, 10) 
is consistent with the suggestion that SAA represents a circulating precursor of 
the fibril protein (4, 5). However, direct evidence that SAA is converted into AA 
is lacking. To elucidate further the relationship between SAA and AA, we have 
studied the serum level of SAA during the development of amyloidosis. For this, 
we have used an animal  model in which amyloidosis was induced in mink by 
repeated endotoxin injections (11).  Endotoxin-induced  amyloid fibrils in mink 
contain a protein equivalent to human AA, and the sera of some mink contain a 
related protein,  mink SAA (12). 
A dramatic increase in the serum level of SAA occurred within 24 h of the first 
endotoxin injection.  Subsequently, the concentration of SAA decreased to rela- 
tively low levels, but increased again during the early amyloidotic phase. 
Materials  and Methods 
Animals.  19 mink (Mustela vision) of the standard type were used, 6 males and 13 females. All 
mink were less than 20-mo old at the beginning of the study. 
Antiamyloid Antiserum.  Rabbits were immunized with alkali-degraded amyloid fibrils (DAM) 
isolated  from  the  liver  of  a  mink  with  endotoxin-induced  amyloidosis  (12).  Before  use,  the 
antiserum was absorbed with pooled normal mink serum. 
Induction  of Amyloidosis.  Escherichia coli  (O26:B6) endotoxin (Difco Laboratories,  Detroit, 
Mich.) was dissolved in sterile saline (2 mg/ml), stored at -20°C, and thawed immediately before 
use.  13  mink  received  subcutaneous  injections  of endotoxin  three  times  each  week  (2-6  mg 
according to body weight).  Four control mink were  similarly injected with sterile saline.  Two 
additional mink received a  single endotoxin injection (5 mg). 
Assessment of Amyloidosis.  Liver,  spleen,  and kidney sections,  were examined for amyloid 
after staining with hematoxylin and eosin,  Congo red, and thioflavine T.  For immunochemical 
analyses 1 g of tissue was homogenized for 5 min in 20 ml phosphate-buffered saline using a VirTis 
"45" homogenizer (VirTis Co., Inc., Gardiner, N. Y.) and then centrifuged at 27,000 g  for 30 min. 
The supernate was discarded and the washing procedure repeated three times. The final tissue 
sediment was dispersed in 4 ml 0.1 M NaOH, allowed to stand at room temperature overnight, and 
adjusted  to  pH  8.5  with  1  M  HC1  (liver)  or  dialysed  for  16  h  against  water  (spleen).  The 
preparations were centrifuged at 27,000 g  for 30 min and the supernates tested for protein AA by 
double diffusion against rabbit antimink DAM. The degree of amyloidosis was graded +,  + +, or 
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+ + +  if the  maximum  dilution  at  which  protein  AA could  be  detected  was  1:1,  1:10,  or  1:100, 
respectively. 
Protein SAA  Concentration.  Serum samples, from blood collected from the ventral tail artery, 
were  stored at  -20°C.  A  semiquantitative estimation of the concentration  of protein  SAA was 
performed  by double-diffusion  analysis of twofold  dilutions of the  sera,  using antimink  DAM. 
There  is  good  agreement  between  the  concentration  of SAA  determined  in  this  way  and  the 
concentration determined by radial diffusion (5). 
Antiendotoxin  Antibodies.  Antibodies to endotoxin were determined by hemagglutination of 
sheep red blood  cells coated  with endotoxin  (13),  employing U-shaped microtiter  plates (Cooke 
Laboratory Products Div., Dynatech Laboratories Inc., Alexandria, Va.). Hemagglutination titers 
were read after the plates were incubated at 37°C for 1 h  and stored overnight at 4°C. 
Results 
Development of  Amyloidosis.  Amyloid was first detected in a mink (mink 9) 
killed 28 days after the commencement of the course of endotoxin (Table I). In 
this mink amyloid was detected in the liver immunochemically but not histolog- 
ically, whereas neither method detected amyloid in the spleen. All mink which 
received a  longer course of endotoxin had  marked  amyloid deposition in both 
liver and spleen,  whereas no evidence of amyloidosis was found in any mink 
receiving endotoxin  for less than  28 days.  No amyloid was found in  the four 
control mink,  which received saline injections for 7 wk. 
Protein SAA Concentration.  There was a  sharp  increase in the concentra- 
tion of SAA after the first endotoxin injection (Fig.  1).  SAA was detectable in 
only four mink before receiving any endotoxin (titers of 1, 4, 4, and 8) but 24 h 
after the first endotoxin injection all mink had a titer of either 64 or 128. During 
the subsequent 3-wk period, and before the deposition of detectable amyloid, the 
concentration  of SAA  in  the  sera  decreased  considerably,  returning  to  near 
control levels at day 21 (Fig. 1). During the amyloidotic phase there was again a 
rise in the concentration of SAA with another subsequent decrease. The concen- 
tration of SAA during the amyloidotic phase never reached that which persisted 
TABLE  I 
Induction  of Amyloidosis  in  Endotoxin-Treated  Mink 
Eyidence of amyloidosis 
Length of 
Mink  endotexin  Histology  Immunochemistry 
treatment 
Liver  Spleen  Kidney  Liver  Spleen 
days 
1  1  ..... 
2  1  ..... 
3  7  .... 
4  7  .... 
5  13  -  -  ND*  ND 
6  13  -  -  -  ND  ND 
7  21  .... 
8  21  ..... 
9  28  -  -  -  +  - 
10  53  +++  +++  -  +++  ++ 
11  53  ++  +++  -  +++  +++ 
12  60  ++  +++  -  +++  ++ 
13  62  +  ++  -  +++  ++ 
No evidence of amyloidosis 
each  week for 7 wk. 
* ND, not determined. 
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Days  after  first  endotoxin  injection 
Concentration of protein SAA:  (i), treated and (it), control; and antiendotoxin 
antibodies: (©), treated and (A), control; during the induction of amyloidosis by repeated 
endotoxin injections. The numbers in parentheses indicate the number of treated animals 
from which the geometric means and standard error of the means were calculated. All the 
control values were calculated from four mink. 
for the first 14 days after the commencement of endotoxin treatment (Fig. 1). 
All four control mink were negative for SAA when tested before receiving the 
first saline injection. At day 1 two of these mink had detectable SAA (a titer of 8 
in each case). One of these mink maintained an elevated level of SAA through- 
out the 7-wk period of the experiment (titers ranged from 2 to 8), whereas the 
other  was  still  positive  at  day  8  (titer  of 4)  but  was  negative  when  bled 
subsequently. Of the other two control mink, one was negative for SAA through- 
out the experiment and the other was negative at all bleeds except day 22 (titer 
of 2).  Thus  the  SAA  concentration did  rise  in  some  control  mink but  was 
consistently much lower than in the mink receiving endotoxin (Fig. 1). Either 
low amounts of endotexin in the saline solution or inflammation resulting from 
the repeated bleeding could have caused the elevation of SAA in the control 
mink. 
As SAA had already risen to high levels when blood was first taken 24 h after 
the first endotoxin injection, two additional mink were given a single subcuta- 
neous injection of endotoxin (5 mg) and blood samples were collected at intervals 
during the subsequent 24-h  period.  To facilitate repeated bleeding the mink 
were anesthetized with nembutal. SAA was first detected at 3 h in one mink and ANDERS  ET  AL.  BRIEF  DEFINITIVE  REPORT  681 
at 6 h  in the other.  One mink died at 6 h, presumably because of a  synergistic 
effect between anesthetic and endotoxin.  In the surviving mink the concentra- 
tion of SAA increased progressively throughout the 24-h period. At 24 h the titer 
of SAA was 64,  consistent with the results of the other experiment. 
Antibodies to Endotoxin.  Hemagglutination assays first detected antibodies 
8 days after the first endotoxin injection at a  time when the concentration  of 
SAA  was  decreasing  (Fig.  1).  Thus,  SAA  was  elevated  before a  detectable 
antibody response to the endotoxin. The highest antibody levels were detected at 
day  15,  about  2  wk  before the  onset of amyloidosis,  but significant  levels of 
antibodies were detectable throughout the amyloidotic phase. 
Additional  Experiments  in  Other  Species.  The  generation  of SAA  after 
endotoxin injection has also been studied in rabbit, mouse, and man. In all these 
species a marked increase in the concentration of SAA was observed within the 
same short period of time, similar to that in the mink. 
Discussion 
Endotoxin,  an  effective amyloidogenic substance  in  various animal  species 
including  mink  (11,  14),  is  reported  here  to  be  a  potent  stimulus  for  the 
generation  of SAA,  the  putative  precursor  of the  amyloid fibril  protein  AA. 
Whereas amyloidosis was first detected after 4 wk of endotoxin treatment,  the 
concentration of SAA in the serum increased rapidly during the 24 h  after the 
first endotoxin injection. Thus, in this animal model, elevation of SAA concen- 
tration  occurs  before  the  deposition  of detectable  amyloid,  as  in  secondary 
amyloidosis in man, where high concentrations of SAA are detected in diseases 
such  as rheumatoid  arthritis  (5),  leprosy (8),  and  tuberculosis (6),  before the 
development of amyloidosis. 
The rise in SAA concentration before the formation of amyloid is consistent 
with  the hypothesis that  SAA  is a  precursor of AA,  and the relatively lower 
levels of SAA found during  the amyloidotic phase may be due in part to the 
conversion of SAA to AA with subsequent deposition in amyloid fibrils.  How- 
ever, the concentration of SAA fell sharply from the early high level well before 
the deposition of detectable amyloid. This suggests that mechanisms other than 
the  formation  of amyloid  fibrils,  for  example,  tolerance  to  endotoxin,  may 
operate to limit the SAA response to later endotoxin injections. 
The onset of amyloidosis 4 wk after the peak SAA concentration suggests that 
an  elevated concentration  of SAA per se is not a  sufficient condition for the 
deposition of AA in amyloid fibrils. Formation of fibrils most likely also depends 
upon other events triggered by recurrent  stimulation  of SAA production.  The 
tendency  for  the  concentration  of SAA  to  increase  again  during  the  early 
amyloidotic phase  suggests  that  the  onset of amyloidosis  may depend  on an 
induced defect of SAA catabolism. 
We have recently established that the 20 amino acid N-terminal  sequence of 
human  SAA is identical to that of AA 1 and,  therefore,  conversion of SAA into 
AA  would  involve  cleavage  of SAA  towards  the  C-terminus.  However,  an 
alternative possibility is that both SAA and AA are derived by proteolysis from 
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a common, larger precursor. The N-terminal heterogeneity in SAA  ~  as in some 
preparations of AA, the rapid appearance of SAA in serum after treatment with 
endotoxin, and the finding of an amyloid fibril protein AA larger than the SAA 
subunit (15) support this suggestion, 
A more common experimental model of amyloidosis is casein-induced amyloi- 
dosis in mice. Investigations with this model to determine whether an antibody 
response to casein is important in the pathogenesis of amyloidosis have given 
conflicting results (16). Our results allow no conclusions as to the importance of 
the  observed  antiendotoxin response  for  the  genesis  of amyloid fibrils  but 
provide clear evidence that such a response is not necessary for the generation of 
SAA. 
Observations in man have indicated that SAA is an acute-phase reactant (6) 
and endotoxin is known to stimulate the synthesis of other acute-phase reac- 
tants. However, unlike the majority of acute phase reactants, SAA  is not a 
glycoprotein (R. F. Anders, unpublished observation), and in one study the 
correlation  between levels  of  SAA and C-reactive protein was poor (6).  Whether 
SAA is synthesized in the liver  as are other acute-phase reactants or is gener- 
ated elsewhere, possibly by proteolytic  degradation of  a precursor molecule, is 
currently under investigation. 
Summary 
The concentration of the amyloid AA-related serum protein (SAA) was mark- 
edly increased after endotoxin injections in mink, mouse, rabbit, and man. It 
was particularly studied during the development of endotoxin-induced amyloi- 
dosis of  the mink. Protein SAA was markedly elevated in all mink 24 h after the 
first endotoxin injection but had fallen to relatively low levels before the onset of 
amyloidosis at  about  4  wk.  These  results  are  consistent with  SAA  being  a 
circulating precursor of the amyloid fibril protein, AA. However, both proteins 
may be derived by proteolysis from a common precursor. 
Received for publication 25 November 1975. 
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